<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199081</url>
  </required_header>
  <id_info>
    <org_study_id>DRONE_C_04629</org_study_id>
    <secondary_id>2010-019247-19</secondary_id>
    <nct_id>NCT01199081</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation</brief_title>
  <acronym>ARTEMIS AF LT</acronym>
  <official_title>A Randomized, International, Multi-center, Open-label Study to Document Pharmacokinetics and Optimal Timing of Initiation of Dronedarone Treatment Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation Whatever the Reason for the Change of Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      - Explore Dronedarone and active metabolite pharmacokinetic (PK) profiles according to
      different timings of Dronedarone initiation.

      Secondary Objective:

        -  Explore potential PK interaction between Dronedarone and Amiodarone

        -  Evaluate the rate of Atrial Fibrillation (AF) recurrence during the study period (from
           randomization up to 60 days after)

        -  To assess the safety of the change from Amiodarone to Dronedarone and Dronedarone safety
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximum study duration per patient is 10 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of dronedarone and its metabolite</measure>
    <time_frame>At randomization (baseline), 3 hours after the first dose of dronedarone, after 1, 2 and 4 weeks of treatment with dronedarone (before dronedarone dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of amiodarone and its metabolite</measure>
    <time_frame>At randomization (baseline), 3 hours after the first dose of dronedarone, after 1, 2 and 4 weeks of treatment with dronedarone (before dronedarone dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with AF recurrence</measure>
    <time_frame>From randomization up to 60 days after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Up to 8 weeks after randomization</time_frame>
    <description>Specific AESIs are: congestive Heart Failure (CHF), Interstitial lung disease , severe skin disorders, peripheral neuropathy including optic neuropathy and increase in alanine aminotransferase (ALT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with symptomatic bradycardia (Heart Rate (HR) &lt; 50 beats per minute at rest)</measure>
    <time_frame>Up to 8 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with symptomatic tachycardia (HR &gt; 120 beats per minute at rest)</measure>
    <time_frame>Up to 8 weeks after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dronedarone 400 mg twice daily for 8 weeks starting from randomization.
The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dronedarone 400 mg twice daily for 6 weeks starting 2 weeks after randomization.
The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dronedarone 400 mg twice daily for 4 weeks starting 4 weeks after randomization.
The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronedarone</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral (together with meal)
Dose regimen: 400 mg twice daily</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>MultaqÂ®</other_name>
    <other_name>SR33589</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Screening:

          -  Paroxysmal or persistent AF having received at least 6 months of amiodarone before
             screening with at least the last 2 months at a regimen of 200 mg/day (during at least
             5 days per week) prior to screening

          -  Requiring a change from amiodarone treatment whatever the reason, but without liver,
             lung or thyroid toxicity related to previous use of amiodarone

          -  At least one cardiovascular risk factor (i.e. age &gt; 70, hypertension, diabetes, prior
             cerebrovascular disease or left atrial diameter &gt;= 50 mm

          -  Effective anticoagulation treatments verified by International Normalized Ratio (INR)
             (target INR &gt; 2)

          -  QTc Bazett &lt; 500 ms on 12-lead ECG

        Randomization:

          -  Outpatients and Inpatients (except patients hospitalized during screening period for
             SAE)

          -  Sinus rhythm

          -  Effective oral anticoagulation treatment verified by INR (target INR &gt; 2). INR should
             be closely monitored after initiating dronedarone in patients taking vitamin K
             antagonist as per their label

          -  QTc Bazett &lt; 500 ms and PR &lt; 280 ms on 12-lead ECG

        Exclusion criteria:

        Screening:

          -  Contraindication to oral anticoagulation

          -  Acute condition known to cause AF

          -  Permanent AF

          -  Bradycardia &lt; 50 bpm at rest on the 12-lead ECG

          -  History of, or current heart failure or left ventricular systolic dysfunction

          -  Unstable hemodynamic conditions

          -  Severe hepatic impairment

          -  Wolff-Parkinson-White Syndrome

          -  Previous catheter ablation for atrial fibrillation or catheter ablation scheduled in
             the next 10 weeks

          -  Previous history of Amiodarone intolerance or toxicity

          -  History of thyroid dysfunction

          -  Mandatory contraindicated concomitant treatment:

               -  potent cytochrome P450 (CYP3A4) inhibitors

               -  drugs or herbal products that prolong the QT interval and known to increase the
                  risk of Torsade de Pointes

          -  Previous treatment with class I or class III anti-arrhythmic drugs (including sotalol)
             other than amiodarone if the anti-arrhythmic drug was taken less than one week before
             the day of screening (if taken more than one week before screening, the patient can be
             included)

        Randomization

          -  Bradycardia &lt; 50 bpm on the 12-lead ECG

          -  History of, or current heart failure or left ventricular systolic dysfunction

          -  Unstable hemodynamic conditions

          -  Severe hepatic impairment

          -  Mandatory contraindicated concomitant treatment:

               -  potent cytochrome P450 (CYP3A4) inhibitors

               -  drugs or herbal products that prolong the QT interval and known to increase the
                  risk of Torsade de Pointes

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 170001</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170002</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170003</name>
      <address>
        <city>Cartagena</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170006</name>
      <address>
        <city>Cartagena</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170007</name>
      <address>
        <city>Floridablanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170005</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203005</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203003</name>
      <address>
        <city>Kladno</city>
        <zip>27280</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203002</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203007</name>
      <address>
        <city>Prachatice</city>
        <zip>38301</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203001</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203004</name>
      <address>
        <city>Praha 9</city>
        <zip>19000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203008</name>
      <address>
        <city>Pribram</city>
        <zip>26101</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203006</name>
      <address>
        <city>Sternberk</city>
        <zip>78501</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208-001</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208-002</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208-003</name>
      <address>
        <city>KÃ¸benhavn S.</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-004</name>
      <address>
        <city>AMIENS Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-005</name>
      <address>
        <city>Boulogne Billancourt Cedex</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-003</name>
      <address>
        <city>Chambray Les Tours Cedex</city>
        <zip>37171</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-002</name>
      <address>
        <city>GRENOBLE cedex</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-001</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250-006</name>
      <address>
        <city>TOULOUSE Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276-001</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276-002</name>
      <address>
        <city>Chemnitz</city>
        <zip>09111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276-005</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276-003</name>
      <address>
        <city>NÃ¼rnberg</city>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276-004</name>
      <address>
        <city>Wermsdorf</city>
        <zip>04779</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484003</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484002</name>
      <address>
        <city>Mexico</city>
        <zip>11340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484001</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>72244</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484005</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484004</name>
      <address>
        <city>Torreon</city>
        <zip>27000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484006</name>
      <address>
        <city>Zapopan</city>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724004</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724005</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724002</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724003</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724006</name>
      <address>
        <city>Valdemoro</city>
        <zip>28342</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <last_update_submitted>June 6, 2013</last_update_submitted>
  <last_update_submitted_qc>June 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

